ArticleDiscover oncology2025
Global, regional, and National burden of metabolic dysfunction-associated steatohepatitis-related liver cancer in older adults: trends and cross-national inequality based on the global burden of disease study 2021.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding the temporal trends of metabolic dysfunction-associated steatohepatitis-related liver cancer (MASH-LC) in older adults is crucial for raising public awareness and informing future policy decisions.
methodsThis is the first study to use Global Burden of Disease (GBD) data to analyze the burden of MASH-LC specifically in adults aged 65 years and older. Utilizing data from GBD 2021, we analyzed the incidence, mortality, and disability-adjusted life years (DALYs) of MASH-LC among individuals aged 65 and older from 1990 to 2021. We also examined corresponding age-standardized rates and conducted stratified analyses based on region, sex, age, and temporal changes. To assess cross-national health inequality, we further applied the slope index of inequality (SII) and concentration index (CI), which have not been previously employed in studies of MASH-LC among older adults.
resultsGlobally, age-standardized incidence, mortality, and DALYs rates (ASIR, ASMR, and ASDR) of MASH-LC in older adults exhibited a significant upward trend, with a higher burden observed in males. The absolute numbers of incidence, deaths, and DALYs increased by 251.59%, 231.08%, and 211.00%, respectively. While ASIR declined notably in high-sociodemographic index (SDI) regions, ASMR and ASDR were highest in low-SDI regions by 2021. China bore the heaviest burden globally, whereas Australia and the United Kingdom experienced the most substantial growth. Cross-national inequality analyses indicate that indicated that the burden of MASH-LC in older adults was more concentrated in low-SDI countries. Additionally, the disease burden escalated with age, with peak burden ages differing slightly between sexes.
conclusionThe global burden of MASH-LC in older adults has risen markedly. Targeted preventive strategies are urgently needed to mitigate disease progression and reduce disparities across populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.